Wishing A Very Happy Birthday To Dr. Charles Wood!


Dr. Charles Wood

Editor-in-Chief: Current HIV Research

Center for Virology School of Biological Sciences

University of Nebraska Rm 102C, Morrison Center 4240 Fair Street Lincoln,

NE 68583-0900 USA

An analysis of the HIV/AIDS Epidemic in Taiwan!

The spread of an HIV epidemic has been recorded since the last 10 years in Taiwan.  Especially amongst those people who inject drugs in their veins. There was a hefty increase in patients suffering from HIV/AIDS since the past 3 years.


The exact number of HIV patients had yet to be reported, hence, a research team conducted a survey using a compartmental mathematical model for disease transmission and HIV/AIDS surveillance data during 2001-2011 in which it was observed that the estimated under reporting ratio in 2011 is 0.45:1 decreased from 1:1 ratio in 2000. Based on the assumption that model parameters remain unaltered, a future prognosis was presented of both the reported and the unreported persons living with HIV/AIDS.

An observed data set from 2012-2014 showed lower than the expected number of persons living with HIV/AIDS and new deaths maybe because of increased treatment. On the other hand, the percentage of newly reported HIV/AIDS patients has increased which further warrants investigation.

For more detail read article: http://benthamscience.com/journals/current-hiv-research/volume/14/issue/2/page/138/

World AIDS Day!


Today marks the World AIDS day. HIV, the virus that causes AIDS, is one of the world’s most serious health and development challenges. Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV).

Bentham Science publishes articles related to AIDS in its high impact journals including :

Current HIV Research

Article by Disease – “HIV-1 Latency and Eradication: Past, Present and Future”

Article by Disease on “HIV”


Abstract :

Background: It is well established that antiretroviral therapy (ART), while highly effective in controlling HIV replication, cannot eliminate virus from the body. Therefore, the majority of HIV-1-infected individuals remain at risk for developing AIDS due to persistence of infected reservoir cells serving as a source of virus re-emergence. Several reservoirs containing replication competent HIV-1 have been identified, most notably CD4+ T cells. Cells of the myeloid lineage, which are the first line of defense against pathogens and participate in HIV dissemination into sanctuary organs, also serve as cellular reservoirs of HIV-1. In latently infected resting CD4+ T cells, the integrated copies of proviral DNA remain in a dormant state, yet possess the ability to produce replication competent virus after cellular activation. Studies have demonstrated that modification of chromatin structure plays a role in establishing persistence, in part suggesting that latency is, controlled epigenetically.< p> Conclusion: Current efforts to eradicate HIV-1 from this cell population focus primarily on a “shock and kill” approach through cellular reactivation to trigger elimination of virus producing cells by cytolysis or host immune responses. However, studies revealed several limitations to this approach that require more investigation to assess its clinical application. Recent advances in gene editing technology prompted use of this approach for inactivating integrated proviral DNA in the genome of latently infected cells. This technology, which requires a detailed understanding of the viral genetics and robust delivery, may serve as a powerful strategy to eliminate the latent reservoir in the host leading to a sterile cure of AIDS.

Read more: http://benthamscience.com/journals/current-hiv-research/volume/14/issue/5/page/431/ 

HIV Treatment – Where Have the Researchers Reached?

HIV, Human Immunodeficiency Virus, has been the deadliest virus discovered in the last century. The virus is feared for its ability to affect the immune system of humans and render them vulnerable to catch any other virus, bacteria or disease that may be around. What’s worse is the contagious nature of HIV, as it can easily transmit through blood diffusion, sexual transmission, cuts and wounds, and also from mothers to babies. The virus has been extremely resistant to medicines and treatments so far, making it a veteran killer of humans.


There has been some recent advancement in administering drugs to HIV patients which have proven promising in keeping the virus from multiplying. Applauding this progress, the researchers have also apprehended that the virus is so resilient that it quickly alters itself through mutation to keep its onslaught going. The drugs can only hold the virus back temporarily and soon they lose their utility.

This has led the researchers to develop computational methods to track the changes occurring in HIV and realize when the right time to change the course of treatment comes. The method can also make the changes predictable and so the scientists will be able to proactively deal with the danger.

The research paper, Current Approaches in Computational Drug Resistance Prediction in HIV, published in Current HIV Research journal presents the study in detail.

Bentham Science Publishers has offered Free Trial to Cipla Ltd.!

Cipla Ltd., India

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development, focuses on developing innovative products and drug delivery systems.


World AIDS Day – 1st Dec

Bentham Science Publishers is observing World AIDS day today. You may find various research articles on this disease on our website. Find more articles in our journal Current HIV Research

banner-World AIDS Day

The Challenge of a “Functional Cure” for AIDS by Gene Modified HSCT Therapy is the article from the journal Current Stem Cell Research & Therapy , 10(6): 492-498,

Acquired immunodeficiency syndrome (AIDS), an infectious disease which is difficult to be cured, is regularly and effectively treated with anti-retroviral therapy in clinic. When considering about the defects of antiretroviral therapy (ART), patients need a new way to cure AIDS. With the development of genetic engineering technology and humanized mouse models, a new way has been found to achieve a “functional cure” for AIDS.


Fact and Myths about HIV/AIDS


%d bloggers like this: